Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Nordic Nanovector. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Nordic Nanovector's earnings available for a low price, and how does
this compare to other companies in the same industry?
Nordic Nanovector's earnings are expected to grow significantly at over 20% yearly.
Nordic Nanovector's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Nordic Nanovector's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Nordic Nanovector's finances.
The net worth of a company is the difference between its assets and liabilities.
Nordic Nanovector is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Nordic Nanovector's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Nordic Nanovector's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Nordic Nanovector has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Eduardo Bravo is Chief Executive Officer of Nordic Nanovector ASA since July 2, 2018. He has more than 25 years of experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations. He served as Chief Executive Officer of TiGenix Since 2011. Prior to joining TiGenix' predecessor, Cellerix, in 2005, he held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He serves as Chairman of Vivet Therapeutics. He holds a degree in Business Administration and an MBA (INSEAD).
Insufficient data for Eduardo to compare compensation growth.
Insufficient data for Eduardo to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Nordic Nanovector management team is less than 2 years, this suggests a new team.
Chief Financial Officer
Chief Operating Officer
Chief Scientific Officer
Chief Human Resources Officer
Chief Medical Officer
Chief Quality Officer
Chief Executive Officer
Vice President of Investor Relations & Corporate Communications
Head of Corporate Development & Strategy
Head of Medical Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Nordic Nanovector board of directors is about average.
Board of Directors
Chairman of the Board
Per Anders Samuelsson
Chairman of Scientific Advisory Board
Chairman of Scientific Advisory Board
Member of Scientific Advisory Board & Member of Clinical Advisory Board
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for haematological cancers. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has research collaborations with INSERM; Dana Farber; Paul Scherrer Institute; Heidelberg Pharma; LegoChemBio; OranoMed; IOR cancer institute; Norwegian Radium Hospital; University of Bergen; and UMCG. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.